BGLC vs ZION · rev $99.0K vs P/E 11, rev $354.0M
BioNexus Gene Lab Corp Common stock (BGLC) versus Zions Bancorporation (ZION) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
Zions Bancorporation (ZION) is a banks - regional company listed on US.
Latest reported BGLC revenue for 2026-06-30 was $99.0K. Net income was -$830.0K. BGLC currently screens at market cap $6.1M.
Latest reported ZION revenue for 2026-06-30 was $354.0M. Net income was $686.0M. ZION currently screens at market cap $8.19B and trailing P/E 10.8.
BGLC currently screens at market cap $6.1M. ZION currently screens at market cap $8.19B and trailing P/E 10.8.
Not investment advice. Open the BGLC and ZION stock pages for the full models.
Not investment advice.